Addex Therapeutics
(NASDAQ: ADXN)
|
8:30 PM UTC, 07/02/24 | |||
---|---|---|---|---|
Last: $7.84 | Change: +0.00 | %Change: +0.06% | Volume: 3,472 |
Open: | $ 7.97 | Volume: | 3,472 | |
---|---|---|---|---|
High: | $ 8.29 | Yield(%) | 0.00 | |
Low: | $ 7.84 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 6.42M | |
EPS ($) | -17.95 | Shares Out: | 819,222.95 |
% Price Change (last 4 weeks): | -12.11 |
---|---|
% Price Change (last 13 weeks): | -40.79 |
% Price Change (last 26 weeks): | 24.48 |
% Price Change (last 52 weeks): | -32.47 |
% Price Change (year to date): | 29.59 |
Return on Equity (%): | -352.40 |
---|---|
Return on Assets (%): | -162.44 |
Return on Invested Capital (%): | -145.22 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | -652.75 |
Operating Profit Margin (%): | -637.60 |
|
|
50-day Moving Average: | $9.27 |
---|---|
200-day Moving Average: | $9.19 |
Avg. Daily Vol. (last 50 days): | 10,087 |
Avg. Daily Vol. (last 200 days): | 11,787 |
52-wk high: | $27.90 |
52-wk low: | $5.00 |
Bid: | $3.14 |
Ask: | $9.89 |
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
|
Addex Therapeutics
9, Chemin des Mines Plan-les-Ouates Geneva GE 1202 Phone: 41.22.884.15.55 Fax: 41.22.884.15.56 http://www.addextherapeutics.com |
Earnings (1year) ($): | -17.95 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 1.71 |
Cash Flow ($): | -14.37 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 2.08 |
Price/Book (x): | 3.53 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 1.46 |
---|---|
Current Ratio (x): | 1.46 |
LT Debt/Equity (x): | 6.15 |
Total Debt/Equity (x): | 30.08 |